1. Home
  2. FTF vs ALLO Comparison

FTF vs ALLO Comparison

Compare FTF & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FTF
  • ALLO
  • Stock Information
  • Founded
  • FTF 2003
  • ALLO 2017
  • Country
  • FTF United States
  • ALLO United States
  • Employees
  • FTF N/A
  • ALLO N/A
  • Industry
  • FTF Finance/Investors Services
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FTF Finance
  • ALLO Health Care
  • Exchange
  • FTF Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • FTF 261.0M
  • ALLO 252.9M
  • IPO Year
  • FTF N/A
  • ALLO 2018
  • Fundamental
  • Price
  • FTF $6.49
  • ALLO $1.18
  • Analyst Decision
  • FTF
  • ALLO Strong Buy
  • Analyst Count
  • FTF 0
  • ALLO 10
  • Target Price
  • FTF N/A
  • ALLO $8.88
  • AVG Volume (30 Days)
  • FTF 153.9K
  • ALLO 2.9M
  • Earning Date
  • FTF 01-01-0001
  • ALLO 11-06-2025
  • Dividend Yield
  • FTF 11.45%
  • ALLO N/A
  • EPS Growth
  • FTF N/A
  • ALLO N/A
  • EPS
  • FTF N/A
  • ALLO N/A
  • Revenue
  • FTF N/A
  • ALLO N/A
  • Revenue This Year
  • FTF N/A
  • ALLO N/A
  • Revenue Next Year
  • FTF N/A
  • ALLO $100.00
  • P/E Ratio
  • FTF N/A
  • ALLO N/A
  • Revenue Growth
  • FTF N/A
  • ALLO N/A
  • 52 Week Low
  • FTF $5.76
  • ALLO $0.86
  • 52 Week High
  • FTF $6.56
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • FTF 64.91
  • ALLO 54.14
  • Support Level
  • FTF $6.39
  • ALLO $1.09
  • Resistance Level
  • FTF $6.45
  • ALLO $1.17
  • Average True Range (ATR)
  • FTF 0.03
  • ALLO 0.07
  • MACD
  • FTF 0.01
  • ALLO 0.01
  • Stochastic Oscillator
  • FTF 91.67
  • ALLO 57.14

About FTF Franklin Limited Duration Income Trust of Beneficial Interest

Franklin Limited Duration Income Trust is a closed-end investment company based in the United States. It conducts its investment to provide high, current income, with a secondary objective of capital appreciation. To align with its investment objective is to invest in a diversified mix of fixed-income securities. Its portfolio is dominated by considerable investments in high-yield corporate bonds while touching upon other avenues such as senior secured floating rate corporate loans, mortgage-backed securities, commercial mortgage-backed securities, asset-backed securities, common stocks, and other short-term investments.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: